publication date: Jul. 31, 2014

Somatuline Demonstrates 65.1 Percent of Gastroenteropancreatic Neuroendocrine Tumor Patients Progression-Free at 96 Weeks

Somatuline increased progression-free survival over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors in a randomized phase III trial.

CLARINET, a double-blind, placebo-controlled study of the antiproliferative effects of Somatuline (lanreotide) Injection 120 mg was conducted in 48 centers across 14 countries.

The data was published in the New England Journal of Medicine, in an article titled “Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors.”

The data gathered from 204 GEP-NET patients showed that placebo-treated patients had a median PFS of 18.0 months and 33.0 percent had not progressed or died at 96 weeks, whereas the median PFS for Somatuline treated patients was not reached, and 65.1 percent had not progressed or died in the same time (stratified logrank test, p<0.001).

This represented a 53 percent reduction in risk of disease progression or death based on a hazard ratio of 0.47 (95% CI: 0.30–0.73). These effects were observed in a population of patients with World Health Organization classification G1 or G2 GEP-NETs, and independent of hepatic tumor volume.

Quality of life measures were not different between the Somatuline and placebo groups, and safety data was consistent with the known safety profile of Somatuline.

“The CLARINET data are compelling, since no similar GEP-NET progression free survival data exist for a somatostatin analogue in such a large, multinational study population,” said Martyn Caplin, professor of gastroenterology and gastrointestinal neuroendocrinology at the Royal Free Hospital in London, and lead author and principal investigator of the study.

Based on the results of the trial, Ipsen, the drug’s sponsor, began a worldwide registration program, and submitted regulatory filings with FDA and for marketing authorization in the … Continue reading CCL July – Somatuline Demonstrates 65.1 Percent of Gastroenteropancreatic Neuroendocrine Tumor Patients Progression-Free at 96 Weeks

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.